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harmacodynamic proﬁling of intravenous antibiotics
gainst gram-negative bacteria collected during the Track-
ng Resistance in the United States Today (TRUST)
urveillance program
. Koomanachai, D.P. Nicolau ∗, J.L. Kuti, C.C. Bulik
Hartford Hospital, 06106, CT, USA
Background: Antibiotic resistance in Gram-negative bac-
illi (GNB) is escalating globally; thus achieving optimal
ntimicrobial exposures has become considerably more
hallenging. We used data from ‘‘Tracking Resistance in
he United States Today (TRUST) surveillance program’’ to
ompare the probabilities of attaining requisite antibiotic
xposures against Escherichia coli, Klebsiella pneumoniae,
cinetobacter baumannii, and Pseudomonas aeruginosa.
Methods: Using Monte Carlo simulation, pharma-
odynamic proﬁling was performed for standard and
rolonged infusions of cefepime 1&2gq12 h, 2gq8h(0.5h&3h
nfusions); ceftazidime 1&2gq8h(0.5&3 h); ceftriax-
ne; 1&2gq24h(0.5 h); ciproﬂoxacin 0.4gq8&12h(1 h);
oripenem 0.5, 1&2gq8h(1&4 h); ertapenem 1gq24h(0.5 h);
mipenem 0.5gq6&8h(0.5 h), 1gq8h(0.5&3 h); lev-
ﬂoxacin 0.75gq24h(1 h); meropenem 0.5gq6&8h(0.5 h)
hen 1&2gq8h(0.5&3 h); piperacillin/tazobactam
.375&4.5gq6h(0.5 h), 3.375gq8h(4 h), 4.5gq6h(3 h).
IC data were incorporated from the 2008 TRUST program.
harmacodynamic targets were deﬁned as fT>MIC >40% for
arbapenems, 50% for penicillins and cephalosporins. A
otal AUC/MIC ≥87 and ≥125 was applied for levoﬂoxacin
nd ciproﬂoxacin, respectively. The cumulative fraction of
esponse (CFR) was determined for each regimen against
ach population of organisms. Optimal CFR was deﬁned a
riori as ≥90%.
Results: The ﬂuoroquinolones displayed the lowest sus-
eptibilities against all organisms. All cephalosporins, car-
apenems and piperacillin/tazobactam had susceptibility
ates >90% for Enterobacteriaceae. Against P. aerugi-
osa, piperacillin/tazobactam portrayed the highest per-
ent susceptibility(90%), followed by meropenem(89.8%),
efepime(88%), and ceftazidime/doripenem(86%). All $-
actam regimens achieved optimal CFR against E. coli,
nd all but piperacillin/tazobactam 3.375 g q6h achieved
ptimal CFR against K. pneumoniae. The ﬂuoroquinolones
chieved the lowest CFRs against all organisms. Against P.
eruginosa, high dose, prolonged infusion doripenem and
eropenem achieved CFRs of 97.2% to 98.8%, followed
y high dose, prolonged infusion ceftazidime(93.3%) and
efepime(93.2%). No regimens achieved optimal CFR against
. baumannii. Prolonged infusion regimens increased CFR for
ll $-lactams against the non-fermenting GNB.
Conclusion: Standard intravenous doses of many com-
only $-lactam regimens have a high probability of
chieving optimal exposure against Enterobacteriaceae. For
on-fermenting-GNB, higher dose, prolonged infusions of
efepime, ceftazidime, doripenem, and meropenem offered
he highest probabilities of achieving bactericidal exposure.
oi:10.1016/j.ijid.2010.02.1922
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ral Ceﬁxime is beneﬁcial in acute uncomplicated
almonella gastroenteritis in children with mucoid or
loody diarrhea — Do indications of antibiotics therapy
eed reassessment?
.-Y. Lee1,∗, T.-Y. Lin2, C.-T. Wu3, C.-H. Chiu3, Y.-C. Huang3
Chang Gung Memorial Hospital and Chang Gung University,
weishan, Taoyuan, Taiwan, R.O.C
Chang-Gung Memorial Hospital, Linkou, Taiwan, R.O.C
Taoyuan, China
Background: Conventional antibiotics not only pro-
ided no beneﬁt to pediatric patients with uncomplicated
almonella enterocolitis but also increased the rate of
elapse and duration of fecal excretion. This study was
esigned to evaluate the role of ceﬁxime, an oral
ephalosporine with excellent activity against Salmonella,
n the treatment of uncomplicated nontyphoid Salmonella
nteritis in children.
Methods: In a randomized, prospective, double-blind,
wo-center study, children with uncomplicated Salmonella
astroenteritis and mucoid/bloody diarrhea were treated
ith oral ceﬁxime (10mg/kg/day divided twice daily) or
lacebo for 5 days. There was no signiﬁcant difference
etween these two groups in their characteristics, sever-
ty of disease and distributions of serogroups (Table 1). The
uration of fever and diarrhea were recorded by hours. Stool
amples were sent for culture weekly until three consecutive
egative results were obtained. Subsequent follow-up visits
ere at any time when diarrhea happened or at two-week
ntervals for the ﬁrst two months, three-month interval for
he following one year and two-year interval for the follow-
ng six years.
Results: Sixty-eight patients with acute, uncompli-
ated culture-proved Salmonella enteritis were enrolled.
erogroup B was the most commonly isolated serogroup
n both oral ceﬁxime group and placebo group (26/37,
4/31), followed by serogroup C (6/37, 3/31) and D
4/37, 4/31). The susceptibility rate of ceﬁxime in vitro
100%) was equal to that of ceftriaxone (100%), and
igher than those of ciproﬂoxacin (97.06%), ceftizoxime
97.06%), sulfamethoxazole-trimethoprim (51.47%), ampi-
illin (42.65%), and chloramphenicol (41.18%).The duration of diarrhea or mucoid diarrhea was signif-
cantly reduced by antibiotic treatment (mean 55.8 hours
s 79.2 hours, p = 0.009; 49.5 hours vs 73.0 hours, p = 0.036)
Table 2). Time to defervescence was signiﬁcantly short-
